Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
BIODESIX INC (BDSX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Biodesix Announces Second Quarter 2023 Results and Highlights Second quarter 2023 Core Lung Diagnostic revenue of $11.4 million increased 58% over the comparable period in 2022 and 33% over the first quarter of 2023; Second quarter 2023 gross profit margin of 73% versus 64% for the second quarter 2022 and 65% for the first quarter 2023; Revenue continues to track to 2023 full year guidance of $52-55 million; Approximately $27.5 million in common shares sold under a private placement from the Company’s largest investors, Board of Directors members, and Executive Leadership team; Multiple publications and data presentations on the clinical utility and health economic benefits of Core Lung Diagnostics tests; Conference Call and Webcast Today at 4:30 p.m. ET BOULDER, CO, August 7, 2023 –"
07/26/2023 8-K Quarterly results
06/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/25/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/11/2023 8-K Quarterly results
Docs: "Biodesix Announces First Quarter 2023 Results and Highlights First quarter 2023 Core Lung Diagnostic revenue of $8.6 million increased 86% over the comparable period in 2022; Record number of Core Lung Diagnostic tests delivered in Company history; Conference Call and Webcast Today at 4:30 p.m. ET BOULDER, CO, May 11, 2023 –"
03/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights Fourth Quarter and Fiscal Year 2022 Core Lung Diagnostic Revenue of $8.2 Million and $29.3 Million Increased 51% and 57% over the comparable 2021 periods, respectively 2023 Total Revenue Guidance Expected to be Between $52 Million and $55 Million - Mid-point of the range represents growth in excess of 60% over 2022 revenues excluding revenues from COVID-19 testing Conference Call and Webcast Today at 8:30 a.m. ET BOULDER, CO, March 6, 2023 –"
12/16/2022 8-K Quarterly results
11/21/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/11/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biodesix Announces Preliminary Revenue for Third Quarter 2022 Third quarter 2022 core lung diagnostic testing revenues growth up 96% to 103% compared to third quarter 2021 Boulder, CO, October 11, 2022"
08/04/2022 8-K Quarterly results
05/25/2022 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/11/2022 8-K Quarterly results
04/11/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events  Interactiv...
Docs: "SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT is entered into this 7th day of April 2022, by and between Biodesix, Inc., a Delaware corporation , and the undersigned . WHEREAS, Subscriber desires to subscribe for and purchase from the Issuer that number of shares of the Issuer’s common stock, $0.001 par value per share set forth on the signature page hereto for a purchase price of $1.79 per share, and for the aggregate purchase price set forth on the signature page hereto , and the Issuer desires to issue and sell to Subscriber the Subscribed Shares in consideration of the payment of the Purchase Price therefor by or on behalf of Subscriber to the Issuer, all on the terms and subject to the conditions set forth herein; and WHEREAS, certain other “qualified institutional buyers&...",
"SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT is entered into this 7th day of April 2022, by and between Biodesix, Inc., a Delaware corporation , and the undersigned . WHEREAS, Subscriber desires to subscribe for and purchase from the Issuer that number of shares of the Issuer’s common stock, $0.001 par value per share set forth on the signature page hereto for a purchase price of $1.79 per share, and for the aggregate purchase price set forth on the signature page hereto , and the Issuer desires to issue and sell to Subscriber the Subscribed Shares in consideration of the payment of the Purchase Price therefor by or on behalf of Subscriber to the Issuer, all on the terms and subject to the conditions set forth herein; and WHEREAS, certain other “qualified institutional buyers&...",
"CONSENT AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT AND THIRD AMENDMENT to Loan and Security Agreement is entered into as of April 7, 2022, by and between SILICON VALLEY BANK, a California corporation and BIODESIX, INC., a Delaware corporation . RECITALS A. Bank and Borrower have entered into that certain Loan and Security Agreement dated as of March 19, 2021 . Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement. B. Borrower has requested that Bank consent to modify Section 6.7 of the Loan Agreement to remove the requirement to satisfy Section 6.7 of the Loan Agreement for the measuring period ending March 31, 2022 . C. Section 7.7 of the Loan Agreement provides that Borrower shall not amend, restate or otherwise modify the Integrated D..."
03/14/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively Full-Scale Launch of GeneStrat NGS™ Test in January 2022 Conference Call and Webcast Today at 8:30 a.m. ET BOULDER, CO, March 14, 2022 –"
03/07/2022 8-K Quarterly results
02/14/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue Core lung diagnostic testing revenues grow 49% for full-year 2021 Boulder, CO, February 14, 2022"
02/14/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue Core lung diagnostic testing revenues grow 49% for full-year 2021 Boulder, CO, February 14, 2022"
01/04/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT AND SECOND AMENDMENT to Loan and Security Agreement is entered into as of December 31, 2021, by and between SILICON VALLEY BANK, a California corporation and BIODESIX, INC., a Delaware corporation . RECITALS A. Bank and Borrower have entered into that certain Loan and Security Agreement dated as of March 19, 2021 . Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement. B. Borrower has requested that Bank consent to modify Section 6.7 of the Loan Agreement to remove the requirement to satisfy Section 6.7 for the measuring period ending December 31, 2021 . C. Borrower has further informed Bank that Borrower intends to make a certain payment owing to the “Seller” as defined t...",
"Investors: Chris Brinzey [email protected] 970-2843"
12/08/2021 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Biodesix Announces Third Quarter 2021 Results and Highlights Third Quarter 2021 Lung Diagnostic Revenue of $4.5 Million Increased 51% over Third Quarter 2020 Company launches 72-hour Next Generation Sequencing test"
09/09/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
01/07/2021 8-K Investor presentation
Docs: "Biodesix Anticipates Strong Preliminary Fourth Quarter 2020 Revenue Record quarterly revenue driven by strength in COVID-19 testing and growth in lung diagnostic testing",
"Corporate Presentation of Biodesix, Inc."
01/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer"
12/10/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Biodesix Announces Third Quarter 2020 Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy